Drug patent litigation isn’t just about molecules—it’s about design choices.
In pharma, “design around” sounds like a strategy. In practice, it’s a discipline: a way to translate patent language into formulation decisions, development timelines, and …

Pharma has a $300 billion problem—and it’s not just about patents. It’s about time.
In the U.S., the patent system doesn’t simply grant rights; it grants a clock. And for brand drugmakers, that clock can mean the difference between funding next-generat…

Pharma has a $300B problem—and it’s not just about patents. It’s about time.
In the U.S., the patent system doesn’t merely grant exclusivity; it also tries to compensate for delays outside a drugmaker’s control. That’s where two concepts—patent term ad…

Pharma executives don’t lose in Eurasia because they “missed a filing.” They lose because they misunderstood the system.
Eurasia—spanning Russia, Kazakhstan, Belarus, Armenia, and beyond—looks familiar on the surface: patents, regulatory approvals, and…

Pharmaceutical patent strategy is often discussed like a binary choice: cut, keep, or cash.
But in practice, it’s a portfolio decision—one that determines whether you’re funding growth or paying for “insurance” that never pays out.
In a recent piece fr…

The clock is ticking—and commercial market access vendors know it.
In pharma, timing isn’t a metaphor. It’s a margin. It’s a formulary. It’s a contract. And increasingly, it’s a race against the “patent clock”—the moment when exclusivity erodes and c…

Before You Launch: The Freedom-to-Operate Checklist That Can Save Your Pharma Program
In pharma, speed is a competitive advantage—until it isn’t. The moment you launch a product, you’re not just entering the market. You’re entering a legal battlefield …

Drug patents in Asia-Pacific: the protection you think you have vs. the protection you actually get
If you’re a pharma executive, investor, or counsel, you already know the headline numbers: patent terms, exclusivity windows, regulatory data protection…